Our approach

Boehringer Ingelheim has sought to develop innovative new medicines for well over 130 years, in a quest to improve the health and wellbeing of society. These new medicines are the result of decades of research, development and clinical testing. Healthcare professionals play a pivotal role along this development process. As new medicines come to market, with the potential to significantly benefit the health and welfare of Australian patients, Boehringer Ingelheim engages in the education of healthcare professionals in Australia to ensure the safe, effective and appropriate use of our medicines.

We also work with healthcare professionals to improve patient care, build shared knowledge and identify future patient needs that can be met through our research and development. This dialogue is critical to ensure that the needs of Australian patients are being best met. We believe that this interaction with healthcare professionals benefits patient care, and enables advances to be made in the therapeutic areas in which the company operates.

We also believe that healthcare professionals who provide independent advice or offer their expertise to develop or deliver appropriate education to relevant audiences should be fairly compensated for their time, services and expertise. Boehringer Ingelheim has for many years supported extensive medical education of Australian healthcare professionals with the aim of improving patient care. Through educational programs accredited by Australian institutions, peer-led meetings, and support of independent scientific meetings, Boehringer Ingelheim is strongly committed to the advancement of patient care.

All of our interactions with Australian healthcare professionals are highly professional, ethical and strictly adhere not only to the company’s high ethical standards, but also to the standards set out in the Medicines Australia Code of Conduct. We fully understand that the community needs to have confidence in these interactions. The pharmaceutical industry, through Medicines Australia has been a leader in the Australian healthcare sector in developing and implementing a robust Code of Conduct that governs these relationships to ensure they are ethical and transparent.

Boehringer Ingelheim is committed to listening and evolving to meet community expectations on how we work with healthcare professionals, while providing important medicines that prevent and treat diseases in Australian patients and ensuring quality education both in regard to therapeutic areas and appropriate use of medicines within these areas.